Reel 08 / the publisher
About Safe NAD.
An independent editorial reel that reviews the NAD+ literature straight — what the trials measured, where the evidence thins, and nothing dispensed or sold.
What this site is
Safe NAD is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ and its precursors. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is a curated reel of the evidence — what made the cut and why. Controlled human findings get foregrounded; the honest gaps get foregrounded too. We label every route (oral precursor versus IV infusion) and every precursor (NMN versus NR), because the marketplace routinely conflates them, and we keep the NAD+-versus-precursor distinction exact: most oral products are precursors, not NAD+ itself.
What 'safe' means here
The word "safe" in the name is an editorial posture, not a claim about any product. It means we read the safety and tolerability record carefully and report it without inflation: the oral-precursor trials that showed no significant adverse-event difference from placebo, the compounded-IV NAD+ Class I endotoxin recall, the contested supplement status of NMN, and the 2025 review's conclusion that human efficacy for hard clinical endpoints remains preliminary. "Safe" is the due-diligence register applied to the literature — a fiduciary read of the evidence, not a storefront and not a promise.
Any modifier in the domain name is editorial framing — a position this publisher occupies relative to the literature, not a description of services we offer. We do not provide treatment, consultation, prescriptions, or sales of any kind.
How we handle citations
Every quantitative statement on this site is tied to a numbered source on the references page, with a DOI and a PubMed link. We describe what specific studies measured — the species, the dose, the route, and the outcome — and we do not extrapolate beyond what a study reported. Where the strongest data come from rodents or cell culture, we say so. Where a claim rests on a single pilot study, we say that too. The goal is a record a reader can verify, not a conclusion a reader is asked to accept on trust.